In the treatment of rheumatoid arthritis, isopsoralen (in vitro: 10, 20 μM; in vivo: 5, 20 mg/kg) could improve inflammatory response by targeting macrophage migration inhibitory factor (MIF) and reducing the release of inflammatory factors [78]. The gene discussed is MIF; the disease is rheumatoid arthritis.